✦ LIBER ✦

Biomarkers as Surrogate Endpoints in Cancer Trials

✍ Scribed by Barbara K. Dunn; Esther Akpa

Book ID: 116888297
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 295 KB
Volume: 28
Category: Article
ISSN: 0749-2081
DOI: 10.1016/j.soncn.2012.03.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biomarkers and surrogate endpoints in cl

Biomarkers and surrogate endpoints in clinical trials

✍ Thomas R. Fleming; John H. Powers 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB

Validation of surrogate endpoint biomark

Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials

✍ Bruce J Trock 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 210 KB

Comparing Biomarkers as Principal Surrog

Comparing Biomarkers as Principal Surrogate Endpoints

✍ Ying Huang; Peter B. Gilbert 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB

A phase II chemoprevention trial design

A phase II chemoprevention trial design to identify surrogate surrogate endpoint biomarkers in breast cancer

✍ Kapil Dhingra 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 434 KB

Surrogate biomarkers for risk assessment and efficacy of potential chemopreventive agents are needed to improve the efficiency and reduce the cost of conducting chemoprevention trials. In addition to criteria of sensitivity, specificity, quantifiability, and reproducibility applicable to most potent

Surrogate endpoints in clinical trials

✍ Lawrence Friedman; Salim Yusuf 📂 Article 📅 1985 🏛 Elsevier Science 🌐 English ⚖ 85 KB

Imaging biomarkers as surrogate endpoint

Imaging biomarkers as surrogate endpoints for drug development

✍ Wolf S. Richter 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 100 KB